 | Up a level |
Journal Article
Braun, M., Gluz, O., Nitz, U., Christgen, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., Kreipe, H. -H. and Harbecks, N. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer. Oncol. Res. Treat., 39. S. 2 - 3. BASEL: KARGER. ISSN 2296-5262
Christgen, M., Harbeck, N., Gluz, O., Raap, M., Christgen, H., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Stefek, A., Krabisch, P., Just, M., Graeser, M., Baehner, R., Wuerstlein, R., Nitz, U., Kates, R. and Kreipe, H. (2020). High likelihood of actionable pDifferential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trialathogenic variant detection in breast cancer genes in women with very early onset breast cancer, but low rate of additional panel genes. Eur. J. Cancer, 138. S. S1 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Degenhardt, T., Gluz, O., Thomssen, C., Vetter, M., Kates, R., Warm, M., Shak, S., Augustin, D., Kusche, M., Untch, M., Paepke, S., Uleer, C., Duennebacke, J., Nitz, U. and Harbeck, N. (2010). Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Onkotype DX and uPA/PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Giuz, O., Kreipe, H., Degenhardt, T., Kates, R., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2011). Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Gluz, O., Erber, R., Kates, R., Kreipe, H., Bartels, A., Liedtke, C., Pelz, E., Huober, J., Kuhn, W., Nitz, U., Hartmann, A., Harbeck, N. and Bruenner, N. (2011). Predictive Value of HER2, Topoisomerase-II (Topo-II) and Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy of Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer Results from the EC -Doc Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Gluz, O., Hofmann, D., Von Schumann, R., Kates, R., Clemens, M., Salem, M., Reimer, T., Liedtke, B., Aktas, B., Stefek, A., Pollmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Augustin, D., Harbeck, N. and Nitz, U. (2014). Febrile neutropenia (FN) and infections under adjuvant chemotherapy of breast cancer with 6 x TC vs. 4 x EC-4 x Doc: Toxicity data of the WSG planB trial. Oncol. Res. Treat., 37. S. 14 - 16. BASEL: KARGER. ISSN 2296-5262
Gluz, O., Kreipe, H., Christgen, M., Salem, M., Clemens, M., Markmann, S., Liedtke, B., Barinoff, J., Aktas, B., Henschen, S., Luebbe, K., Shak, S., Baehner, R., Liedtke, C., Nitz, U. and Harbeck, N. (2010). Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX (R) and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Gluz, O., Kreipe, H. H., Kates, R. E., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Salem, M., Liedtke, B., Aktas, B., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2012). Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Gluz, O., Nitz, U., Christgen, M., Kates, R., Clemens, M., Kraemer, S., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Lorenz-Salehi, F., Krabisch, P., Just, M., Augustin, D., Liedtke, C., Svedman, C., Shak, S., Wuerstlein, R., Kreipe, H. and Harbeck, N. (2016). Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. Eur. J. Cancer, 57. S. S6 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Gluz, O., Nitz, U., Christgen, M., Malter, W., Clemens, M., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Ppllmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Kuemmel, S., Liedtke, C., Shak, S., Kates, R., Wurstlein, R., Kreipe, H. H. and Harbeck, N. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Gluz, O., Nitz, U., Kreipe, H. H., Christgen, M., Kates, R. E., Hofmann, D., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., Kusche, M., Heyl, V., Lorenz-Salehi, F., Just, M., Liedtke, C., Wuerstlein, R. and Harbeck, N. (2015). Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX (R): First prospective survival results from the WSG phase III planB trial. Eur. J. Cancer, 51. S. S311 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Harbeck, N., Gluz, O., Christgen, M., Braun, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., de Haas, S. L., Kiermaier, A., Kreipe, H. H. and Nitz, U. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Gluz, O., Kreipe, H. H., Christgen, M., Svedman, C., Shak, S., Hofmann, D., Kuemmel, S., Nuding, B., Rezai, M., Schumacher, C., Kusche, M., Forstbauer, H., Maass, N., Kraemer, S., Aktas, B., Mohrmann, S., Wuerstlein, R., Kates, R. E. and Nitz, U. (2013). Run-in phase of prospective WSG-ADAPT HR+/ HER2-trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C. M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R. J., Kates, R. E., Zu, C. Eulenburg, Wuerstlein, R., Kreipe, H. and Gluz, O. (2021). Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial. Ann. Oncol., 32. S. S1285 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Malter, W., Forstbauer, H., von Schumann, R., Just, M., Jozwiak, K., Hauptmann, M., Kates, R., Graeser, M., Wuerstlein, R. and Kreipe, H. (2020). De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results. Ann. Oncol., 31. S. S1146 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Huober, J., Gluz, O., Hartmann, A., Kates, R., Kreipe, H. H., Pelz, E., Thomssen, C., Fischer, H. H., Moebus, V., Augustin, D., Weiss, E., Erber, R., Liedtke, C., Kuhn, W., Nitz, U. and Harbeck, N. (2010). Evidence for Predictive and Prognostic Impact of Molecular Classification in Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer An Analysis of the WSG EC-Doc Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Liedtke, C., Gluz, O., Heinisch, F., Feuerhake, F., Kreipe, H. H., Clemens, M., Nuding, B., Kraemer, S., Reimer, T., Svedman, C., Shak, S., Nitz, U., Kates, R. E., Harbeck, N. and Christgen, M. (2016). Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) A translational analysis of the prospective WSG planB trial. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Liedtke, C., Gluz, O., Heitz, F., Freudenberger, M., Wuestlein, R., Hungermann, D., Ortmann, M., Kates, R. E., Nitz, U., du Bois, A., Fehm, T. N. and Harbeck, N. (2010). Persistent Triple-Negative Phenotype Is Associated with Poorest Outcome among Patients with Metastatic Breast Cancer (BC) - Results of the Retrospective Multicenter PriMet Study Comparing Molecular BC Phenotypes in Primary Tumors and Corresponding Recurrences. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nitz, U., Gluz, O., Kreipe, H., Christgen, M., Kates, R. E., Clemenss, M., Kraemer, S., Aktas, B., Kuemmel, S. and Harbeck, N. (2015). Risk assessment by St.Gallen 2013 recommendation and Oncotype DX (R): results from the WSG PlanB trial. Breast, 24. S. S110 - 1. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080
Nitz, U., Gluz, O., Kreipe, H., Christgen, M., Kates, R. E., Clemenss, M., Kraemer, S., Aktas, B., Kuemmel, S. and Harbeck, N. (2015). Risk assessment by St.Gallen 2013 recommendation and Oncotype DX (R): results from the WSG PlanB trial. Breast, 24. S. S110 - 1. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080
Nitz, U., Gluz, O., Krepe, H., Liedtke, B., Aktas, B., Henschen, S., Pollmanns, A., Krabisch, P., Zuna, I., Shak, S., Thomsseen, C. and Harbeck, N. (2011). First Interim Toxicity Analysis of the Randomized Phase III WSG Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast Cancer Patients with HER2 Negative Breast Cancer (BC). Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nitz, U., Gluz, O., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Kuemmel, S., Zuna, I. and Harbeck, N. (2011). Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Duennebacke, J., Belzl, N., Augustin, D., Kates, R. E. and Harbeck, N. (2014). Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann. Oncol., 25 (1). S. 75 - 82. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Wuerstlein, R., Gluz, O., Kreipe, H., Kates, R., Degenhardt, T., Liedtke, C., Shak, S., Nitz, U. and Harbeck, N. (2011). Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis). Eur. J. Cancer, 47. S. S33 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049